Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Boily, Gino; Villeneuve, Jean‐Pierre; Lacoursière, L; Chaudhury, Prosanto; Couture, Félix; Ouellet, Jean-François; Lapointe, Réal; Goulet, Stéphanie; Gervais, Normand

doi:10.1111/hpb.12273

Cited by 22 publications

(17 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this result was associated with significant heterogeneity (χ 2 = 5.77, P = 0.06, I 2 = 65%), and the difference between the techniques disappeared in sensitivity analysis. We conclude from the available evidence that the two treatments are associated with similar OS, as suggested by a recent review …”

Section: Discussionsupporting

confidence: 67%

Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma

Xie

Wang

Peng

et al. 2014

Hepatology Research

View full text Add to dashboard Cite

Aim: Conventional transarterial chemoembolization (cTACE)is widely used for treating patients with inoperable hepatocellular carcinoma (HCC). A variation on the technique based on drug-eluting beads (DEB-TACE) has recently entered the clinic, but trials of its safety and efficacy have given conflicting results. This systematic review aimed to gain a current, comprehensive picture of how DEB-TACE compares with cTACE.Methods: MEDLINE, EMBASE, the Cochrane Library, the Chinese National Knowledge Infrastructure database and clinical trial registries were searched through June 2014. Risk ratios (RR), hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Results:The analysis included four randomized controlled trials, one uncontrolled prospective study and one prospective case-control study, altogether involving 652 patients. Overall survival benefit was similar between cTACE and DEB-TACE patients (HR = 1.07, 95% CI = 0.82-1.40, P = 0.875). However, DEB-TACE was associated with a significantly higher objective tumor response rate (RR = 1.14, 95% CI = 1.01-1.29, P = 0.03) and a slightly lower incidence of adverse events. Conclusion:Though the available evidence suggests that although DEB-TACE is associated with better tumor response and potentially fewer adverse events, it does not provide greater survival benefit than cTACE. These results need to be validated in high-quality trials with large sample size.

show abstract

Section: Discussionsupporting

confidence: 67%

Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma

Xie

Wang

Peng

et al. 2014

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…However, tea was associated with higher rates of fever and pain. Studies of tare are limited to retrospective, observational designs 74 . Overall, tare and tea are intriguing technologies with some suggestion that they could improve outcomes; randomized trials are warranted.…”

Section: Summary Of Evidencementioning

confidence: 99%

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Bossé

Ahmad

et al. 2016

Current Oncology

View full text Add to dashboard Cite

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016 was held in Montreal, Quebec, 5-7 February. Experts in radiation oncology, medical oncology, surgical oncology, and infectious diseases involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics:■ Follow-up and survivorship of patients with resected colorectal cancer ■ Indications for liver metastasectomy ■ Treatment of oligometastases by stereotactic body radiation therapy ■ Treatment of borderline resectable and unresectable pancreatic cancer ■ Transarterial chemoembolization in hepatocellular carcinoma ■ Infectious complications of antineoplastic agents

show abstract

“…The Slotta JE et al . HCC: Current management and perspectives recently published Canadian clinical recommendations also state that TACE probably provides benefit and thus also recommend TACE for patients with intermediate stages of HCC [66] . Furthermore, TACE is used regularly as a bridging therapy for patients with HCC on the waiting list for liver transplantation.…”

Section: Tacementioning

confidence: 99%

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives

Slotta

Kollmar

Ellenrieder

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed. EPIDEMIOLOGYHepatocellular carcinoma (HCC) is a very common malignant disease with more than 700000 new patients diagnosed per year. Interestingly, the incidence of HCC varies relevantly throughout the world. Whereas HCC is a very common malignant disease in sub-Saharan Africa, and central and south-east Asia with incidence rates of 20-47/100000 habitants, the incidence of REVIEW Submit a

show abstract

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Cited by 22 publications

References 73 publications

Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma

Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives

Contact Info

Product

Resources

About